SCHEMBL1642023

SCHEMBL1642023

O=C(Nc1cccc(-c2ncsc2-c2ccnc(Cl)n2)c1)c1cc(F)ccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCLAT1 Q6UWP7 2/20 0.47
BRAF P15056 2/20 0.46
FADS1 O60427 1/20 0.42
EGFR P00533 3/20 0.41
ERBB2 P04626 2/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 1/20 0.40
BTK Q06187 1/20 0.40
ANO1 Q5XXA6 1/20 0.39
ANO2 Q9NQ90 1/20 0.39
ABL1 P00519 1/20 0.39
PDGFRB P09619 1/20 0.39
BCR P11274 1/20 0.39
PDGFRA P16234 1/20 0.39
HTT P42858 1/20 0.39
MAPT P10636 2/20 0.39
TRPV1 Q8NER1 1/20 0.38
CNR1 P21554 1/20 0.38
ALDH1A2 O94788 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641900 0.88 MAPT (0.47) BRAFEGFRERBB2LMNASMN1; SMN2
SCHEMBL1641998 0.86 LCLAT1 (0.46) LCLAT1BRAFFADS1EGFRERBB2
SCHEMBL1640558 0.86 LCLAT1 (0.45) LCLAT1BRAFFADS1EGFRLMNA
SCHEMBL1640608 0.86 BRAF (0.47) LCLAT1BRAFFADS1EGFRERBB2
SCHEMBL1642305 0.83 LCLAT1 (0.43) LCLAT1BRAFFADS1EGFRLMNA
SCHEMBL1640619 0.80 LCLAT1 (0.49) LCLAT1BRAFFADS1EGFRLMNA
SCHEMBL1641931 0.80 IGF1R (0.53) EGFRERBB2ABL1PDGFRBBCR
SCHEMBL12726574 0.80 ABL1 (0.43) BRAFEGFRERBB2ABL1PDGFRB
SCHEMBL1642090 0.78 SLC2A1 (0.47) BRAFEGFRERBB2ABL1PDGFRB
SCHEMBL3442012 0.78 SLC2A1 (0.55) LCLAT1BRAFFADS1EGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2231625-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-29 EP disclosed
WO-2010020896-A2 SUBSTITUTED IMIDAZOLE COMBINATIONS PFIZER INC. (US) 2010-02-25 WO disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 LCLAT1 2338/4885BRAF 151/4885FADS1 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.